|Src Kinase Inhibitor KX2-391 (Code C74077)|
|Terms & Properties|
Preferred Name: Src Kinase Inhibitor KX2-391
Definition: An orally bioavailable small molecule Src kinase inhibitor with potential antineoplastic activity. Unlike other Src kinase inhibitors which bind to the ATP-binding site, Src kinase inhibitor KX2-391 specifically binds to the peptide substrate binding site of Src kinase; inhibition of kinase activity may result in the inhibition of primary tumor growth and the suppression of metastasis. Src tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation and metastasis.
NCI-GLOSS Definition: A substance being studied in the treatment of cancer. KX2-391 blocks an enzyme needed for growth of cells and may kill cancer cells. It is a type of Src kinase inhibitor.
Display Name: Src Kinase Inhibitor KX2-391
Label: Src Kinase Inhibitor KX2-391
NCI Metathesaurus Link: C2348411 (see NCI Metathesaurus info)
Synonyms & Abbreviations: (see Synonym Details)
|Src Kinase Inhibitor KX2-391|
External Source Codes:
|PDQ Closed Trial Search ID||590687|
|PDQ Open Trial Search ID||590687 (check for NCI PDQ open clinical trial info)|
|Name||Value (qualifiers indented underneath)|
Additional Concept Data:
|Defined Fully by Roles: No|